Abstract. Nemo-like kinase (NLK), a serine/threonine protein kinase, was previously reported to be associated with tumor proliferation and invasion. The present study aimed to evaluate whether NLK participates in the tumorigenesis and progression of colorectal cancer (CRC). NLK expression was examined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis in 50 paired CRC tissues as well as immunohistochemical analysis of 406 cases of primary CRC tissues and paired non-cancerous tissues. Correlations between NLK expression, the clinicopathological features of CRC patients and clinical outcome were then analyzed. NLK expression was found to be significantly higher in CRC tissues as well as associated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion and advanced tumor stage. Patients with NLK-positive tumors demonstrated higher rates of recurrence and mortality than patients with NLK-negative tumors. Multivariate analyses revealed that NLK expression was an independent factor for overall survival [hazard ratio (HR)=0.035; 95% confidence interval (CI)=0.02-0.19; P<0.001] and disease-free survival (HR=0.033; 95% CI=0.007-0.09; P<0.001) in CRC patients. In conclusion, the results of the present study indicated that NLK may serve as a novel biomarker for tumor recurrence and survival for CRC patients.
Introduction
Colorectal cancer (CRC) is a prevalent type of cancer, which has a high mortality rate worldwide (1) . In Europe and the USA, CRC is the third most common type of human cancer and the second leading cause of cancer-associated mortality (2, 3) . In China, the incidence of CRC has risen steadily over the last few decades, with increasing morbidities in younger patients (<50 years) (4) . Recent cancer statistics have indicated that CRC accounts for ~9% of all cancer-associated mortalities (5) . The survival rate of CRC is higher with earlier diagnoses followed by treatment with surgical resection; however, the long-term survival and prognosis of the patients at stages III and IV remain poor (6) . Genes associated with mutations in TP53 (7), KRAS (8, 9) and BRAF (9,10) as well as defective DNA mismatch repair (11) have been investigated for their prognostic and predictive value in CRC; however, the application of these markers requires validation in clinical practice and further evaluation. Sensitive biomarkers enable an early diagnosis and prognosis prediction; therefore, novel factors for predicting tumor recurrence and prognosis following surgery are urgently required.
The Wnt signaling pathway and its downstream components have a role in the regulation of cancer progression through numerous processes, including tumor initiation, tumor growth, cell senescence, cell death, differentiation and metastasis (12) . The Wnt signaling pathway molecule Nemo-like kinase (NLK) is a member of the extracellular-signal regulated kinase/mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase families (13) . NLK was reported to induce apoptosis and inhibit androgen receptor-mediated transcriptional activity in prostate cancer cells (14) . However, NLK also contributes to tumor growth via the activation of cell cycle proteins cyclin D1 and cyclin-dependent kinase 2 in human hepatocellular carcinoma (15) . NLK was also demonstrated to induce apoptosis in glioma cells via activation of caspases (16) . These previous studies have indicated that NLK may be a critical regulator of tumor growth and development. In the present study, reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical RNA extraction and RT-qPCR. Total RNA extraction of 50 paired freshly frozen primary tumor and adjacent normal mucosa (10 cm away from the original tumor site) of CRC specimens were performed according to the manufacturer's instructions (Qiagen, Shanghai, China). A Reverse Transcription kit (Qiagen) was used to reverse transcribe total RNA according to the manufacturer's instructions. Quantitative PCR was performed using a SYBR Green PCR kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions. The human NLK gene was amplified using a commercial NLK qPCR Primer Pair (NM_016231; OriGene, Rockville, MD, USA) and β-actin (HP204660; OriGene) was used as the internal control. Cycling conditions were as follows: Denaturation (5 min at 93˚C) followed by 40 cycles of denaturation (30 sec at 93˚C), annealing (15 sec at 58˚C) and elongation (1 min at 72˚C). Each reaction was performed in triplicate and the 2 -ΔΔCt method was used to calculate relative expression.
Western blot analysis. Western blot analysis was performed as previously described (17) . Monoclonal human anti-NLK antibodies (1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and monoclonal anti-β-actin antibodies (1:2,000; Beyotime Biotechnology, Jiangsu, China) were used as primary antibodies. Immunoreactive bands were detected using a Phototope-horseradish peroxidase western blot detection kit (Cell Signaling Technology, Inc.). For densitometric analysis, NLK protein bands on the blots were measured using Image J software (National Institutes of Health, Bethesda, MD, USA) following normalization to the corresponding β-actin expression levels.
Immunohistochemical analysis. Paraffin-embedded sections fixed in formalin were deparaffinized, rehydrated and incubated with 3% hydrogen peroxidase (Qiagen). The sections were then heated in a microwave oven (1,000 Watts 8503; Kenmore, Chicago, IL, USA) for 3 min at 100˚C for antigen retrieval. Slides were incubated with blocking serum (Qiagen) and primary antibodies for NLK (1:100) overnight at 4˚C. The immunohistochemical reaction was visualized using 0.05% diaminobenzidine followed by counterstaining with hematoxylin. Sections were then examined and analyzed using a microscope (Leica M80; Leica Microsystems, Wetzlar, Germany). Negative control sections were incubated with preimmune rabbit serum (Qiagen) instead of the primary antibodies.
Immunostaining was defined independently using two pathologists blinded to the clinical data and scored by multiplying the staining intensity and the percentage of the stained tumor cells. Staining intensity was graded from 0-3 and the percentage of the stained tumor cells was graded as follows: 0, <5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, >75%. Final scores ranged from 0 to 12. Samples with overall scores from 0-4 were defined as negative expression, while the samples with scores 5-12 were grouped and defined as positive expression (18) . Specimens with inconsistent scores were re-evaluated by two pathologists until an agreement was reached.
Statistical analysis. For categorical variables, values are expressed as the numerical count and the χ 2 test or Fisher's exact test were used to determine the statistical significance of differences between NLK and clinicopathological variables. Kaplan-Meier curves with log-rank tests represented the cumulative survival rate for OS and DFS using NLK expression levels. The Cox proportional hazards model was used to calculate univariate and multivariate hazard ratios for the study variables. P<0.01 was considered to indicate a statistically significant difference between values. All statistical analyses were performed using the SPSS 17.0 statistical software package (SPSS, Inc., Chicago, IL, USA).
Results

NLK upregulation in CRC tissues.
Among the 50 paired specimens available for RT-qPCR analysis, the relative expression levels of NLK mRNA showed a minimum of a two-fold increase in 78.0% of tumor tissues compared to those of the adjacent normal mucosa (Fig. 1) . This therefore suggested that NLK expression was upregulated in CRC tissues.
In addition, western blot analysis was used to confirm these results in the examined 50 paired tumors and corresponding normal tissues. The positive rate of NLK expression was 66.0% in CRC tissues and 18.0% in the matched non-cancerous normal tissues; therefore, NLK expression was significantly higher in CRC tissues than that in the matched normal colorectal tissues (P<0.01) ( Fig. 2A  and B) .
Correlation between NLK expression and clinicopathological features in CRC.
In order to further analyze the clinical and pathological features of NLK expression, immunohistochemical analysis was used to detect NLK protein expression in 406 cases of CRC and paired adjacent noncancerous tissues (Fig. 3) . The Table I . NLK expression in adjacent normal mucosa, cancerous tissues and LNM tissues. results demonstrated that 89.7% of non-cancerous specimens were negative for NLK expression; by contrast, 57.6% of CRC specimens exhibited positive NLK expression. In addition, among the 132 LNM tissues, 90.9% displayed positive NLK expression (Table I) . The correlations between NLK protein expression and clinicopathological features are shown in Table II . The positive expression of NLK was significantly correlated with the depth of tumor invasion, LNM, distant metastasis, vascular invasion and histological differentiation. No significant correlations were observed between NLK expression and age or gender. NLK expression levels were found to be significantly higher in the nodal metastasis than those of the CRC and noncancerous tissues (P<0.001). These data indicated that increased NLK expression may correlate with CRC metastasis.
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CRC patient survival, Kaplan-Meier curves using log-rank tests for OS and DFS were performed. As shown in Fig. 4 , patients with positive NLK expression showed decreased rates of OS and DFS, respectively. In addition, patients with positive NLK expression had a higher recurrence rate than patients with negative expression (P<0.001; data not shown). As shown in Table III 
Discussion
The results of the present study have demonstrated the correlation between elevated NLK expression and human CRC prognosis; of note, correlations were observed between positive NLK expression and aggressive features of CRC, including tumor depth, lymph node metastasis and distant metastasis. This therefore indicated the potential use of NLK as a tumor biomarker for CRC; furthermore, these results suggested that NLK may be used as a novel prognostic marker for more aggressive phenotypes of CRC patients following surgical resection. The NLK gene, which encodes a proline-directed MAPK family member, was identified in 1994 (19) . Functional analyses have demonstrated that NLK contributed to numerous signaling pathways via its ability to phosphorylate diverse transcription factors (20) . NLK was reported to be a pivotal regulator of the Wnt/β-catenin signaling pathway (21) . In addition, NLK has also been shown to regulate the activity of multiple transcription factors, including NF-κB, Smads and p53 (22) . Therefore, the reported involvement of NLK in numerous signaling pathways has demonstrated its vital role in mediating cell signals. Studies of NLK function in human cancers have also confirmed the role of NLK in cell growth and proliferation. In addition, NLK was reported to function as a tumor suppressor gene or an oncogene in different types of cancers; for example, data have demonstrated that NLK expression was decreased during prostate cancer progression and indicated that NLK inhibited androgen receptor (AR) expression and subsequent AR-mediated transcription as well as promoted apoptosis in prostate cancer cell lines (14) . In a previous study, clinicopathological analysis revealed that NLK expression levels were significantly higher in human glioma tissues compared with those of lower grade tumors and the survival rate of glioma patients expressing low levels of NLK was significantly decreased compared to that of patients with gliomas expressing high levels of NLK (16) . Conversely, NLK was reported to act as an oncogene in certain types of tumors. A previous study demonstrated the mitogenic potential of NLK in hepatocellular carcinomas through siRNA-mediated disruption of NLK, which was shown to inhibit proliferation of Hep3B cells and arrest cell cycle transition (15) . These discrepancies may be due to the different pathologies of the types of tumors being studied. In the present study, NLK expression was shown to be significantly upregulated in CRC tissues compared to that of the paired non-cancerous samples, indicating the involvement of NLK in CRC progression.
A recent study reported that NLK overexpression was associated with the progression of gallbladder cancer and that NLK may have potential for use as a prognostic marker (23) . Therefore, the present study aimed to analyze the correlations between NLK expression and the clinicopathological features of CRC patients as well as clinical outcome. These results revealed that positive NLK expression was significantly correlated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion and advanced tumor stage. Kaplan-Meier survival analysis demonstrated that positive NLK expression was negatively correlated with the decreased overall survival rate of CRC patients. Of note, Cox multivariate analysis revealed that NLK expression was an independent factor in predicting OS and DFS for CRC patients. In conclusion, the results of the present study indicated that NLK may have a crucial role in promoting the aggressive phenotypes of CRC and therefore may have the potential for use as a prognostic marker of CRC.
